Renalytix AI plc Total Liabilities

Latest as of December 2024: GBX12.81 Million GBX ≈ $1.56K USD

Renalytix AI plc total liabilities. Based on the latest financial reports, Renalytix AI plc (RENX) has total liabilities worth GBX12.81 Million GBX (≈ $1.56K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Renalytix AI plc (RENX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Renalytix AI plc (2012–2025)

Total liabilities of Renalytix AI plc from 2012 to 2025. This chart illustrates how Renalytix AI plc's total liabilities have evolved over time, based on quarterly financial data. Explore Renalytix AI plc (RENX) investment intensity to see how much of total assets are deployed in long-term investments.

Renalytix AI plc Competitors by Total Liabilities

The table below lists competitors of Renalytix AI plc ranked by their total liabilities.

Company Country Total Liabilities
TTA Holdings Ltd
AU:TTA
Australia AU$594.78K
Amigo Holdings PLC
LSE:AMGO
UK GBX39.20 Million
Itaconix plc
LSE:ITX
UK GBX3.22 Million
Tongaat
JSE:TON
South Africa ZAC7.30 Billion
Multistack International Ltd
AU:MSI
Australia AU$2.90 Million
First Property Group plc
LSE:FPO
UK GBX19.18 Million
Elixxer Ltd
V:ELXR
Canada CA$17.22 Million
Altair Resources Inc
V:AVX
Canada CA$3.11 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Renalytix AI plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RENX total assets.

Liquidity & Leverage Metrics

Renalytix AI plc Total Liabilities Ratios Explained

Renalytix AI plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.43 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -9.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Renalytix AI plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Renalytix AI plc (2012–2025)

The table below shows the annual total liabilities of Renalytix AI plc from 2012 to 2025.

Year Total Liabilities Change
2025-06-30 GBX13.10 Million
≈ $1.59K
-17.22%
2024-06-30 GBX15.83 Million
≈ $1.93K
-99.97%
2023-12-31 GBX54.50 Billion
≈ $6.63 Million
+230225.83%
2023-06-30 GBX23.66 Million
≈ $2.88K
+17.79%
2022-06-30 GBX20.09 Million
≈ $2.44K
+168.71%
2021-06-30 GBX7.48 Million
≈ $909.61
+40.10%
2020-06-30 GBX5.34 Million
≈ $649.24
+606.75%
2019-06-30 GBX755.00K
≈ $91.86
+1043.68%
2018-06-30 GBX66.02K
≈ $8.03
-100.00%
2016-12-31 GBX41.52 Billion
≈ $5.05 Million
+5.56%
2015-12-31 GBX39.33 Billion
≈ $4.79 Million
-3.76%
2014-12-31 GBX40.87 Billion
≈ $4.97 Million
-3.33%
2013-12-31 GBX42.28 Billion
≈ $5.14 Million
+6.03%
2012-12-31 GBX39.87 Billion
≈ $4.85 Million
--

About Renalytix AI plc

LSE:RENX UK Health Information Services
Market Cap
$289.79K
GBX2.38 Billion GBX
Market Cap Rank
#31263 Global
#986 in UK
Share Price
GBX5.45
Change (1 day)
+0.00%
52-Week Range
GBX1.80 - GBX7.25
All Time High
GBX1220.00
About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more